Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Immunogenicity of SAR440894 in Healthy Adults
NCT04441905Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2020
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EVT894 in chikungunya virus infection (5 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of Adverse Events, Frequency of Serious Adverse Events and 6 more. Started Oct 2020; status: completed.
02
Drugs
EVT894
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT04441905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441905.